We analyzed the incidence and risk factors for ocular GVHD in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Korea. In this retrospective, noncomparative, observational study, 635 subjects were included who had at least 2 years of follow-up ophthalmological examinations after allo-HSCT from 2009 to 2012 at Seoul St Mary's Hospital, Seoul, Korea. The mean duration between allo-HSCT and onset of ocular GVHD was 225.5 ± 194.3 days. The adjusted incidence for acute ocular GVHD was 1.33% and that for chronic GVHD was 33.33%. In the multivariate analysis, preexisting diabetes mellitus (odds ratio (OR): 4.22, 95% confidence interval (CI): 1.66-10.72), repeated allo-HSCT (OR: 29.10, 95% CI: 1.02-8.28) and the number of organs that chronically developed GVHD by stage I (OR: 14.63, 95% CI: 9.81-21.84) increased risk of ocular GVHD. Careful monitoring of ocular GVHD is needed in patients with chronic GVHD in multiple organs and preexisting diabetes.

Purpose To identify vitreoretinal complications in patients after hematopoietic stem cell transplantation (HSCT). Methods Patients with hematologic diagnosis after HSCT were enrolled this study at St. Mary’s Hospital, Korea from 2009 to 2012. Among them, we included the patients who have survived more than 2 years at least since they transplanted. The frequency and subgroup analysis of patients with vitreoretinal complications were done. From the medical records, we confirmed the prognosis of them. As a factor associated with vitreoretinal complications, the occurrence of ocular graft‐versus‐host disease (GVHD) was also analyzed. Results Total 635 patients were included in this study. There were 207 patients with CMV viremia, 16 (2.52 %) patients was diagnosed as CMV retinitis among them. 24 (3.78 %) patients was diagnosed as retinal hemorrhage. In addition, there were 5 (0.79 %) patients with uveitis, 2 (0.31 %) patients with non‐proliferative diabetic retinopathy, 1 (0.16 %) patients with optic neuropathy, 1 (0.16 %) patients with retinal detachment, 1 (0.16 %) patient with central serous chorioretinopathy, 1 (0.16 %) patient with central retinal vein occlusion, 1 (0.16 %) patient with age‐related macular degeneration, and 1 (0.16 %) patient with endophthalmitis. Most of them had regular follow‐up without ocular treatments for retinal complications. In subgroup analysis, there was no significant difference in the incidence of ocular GVHD between groups which had vitreoretinal complications or not. Conclusion The vitreoretinal complications is not usual event in patients who received HSCT. Most of them had good prognosis for retinal complications. The occurrence of vitreoretinal complications was not associated with ocular GVHD.